Inflammatory markers in coronary artery disease

BioFactors

Volumn 38, Issue 5, 2012, Pages 320-328

  Ikonomidis, Ignatios ^a   Michalakeas, Christos A ^a   Parissis, John ^a   Paraskevaidis, Ioannis ^a   Ntai, Konstantina ^a   Papadakis, Ioannis ^a   Anastasiou Nana, Maria ^a   Lekakis, John ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Acute coronary syndromes; Biomarkers; Cardiovascular risk; Coronary artery disease; Inflammation

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; DARAPLADIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; OSTEOPROTEGERIN; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SEROTONIN UPTAKE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHLAMYDIAL PNEUMONIA; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DEPRESSION; DISEASE COURSE; DRUG MECHANISM; HUMAN; HYPERLIPIDEMIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; CORONARY VESSELS; CYTOKINES; DISEASE PROGRESSION; HUMANS; INFLAMMATION; LEUKOCYTE COUNT; LEUKOCYTES; NITRIC OXIDE SYNTHASE TYPE II;

EID: 84867692044     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.1024     Document Type: Review

References (86)

1. Ross, R. (1999) Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340, 115-126.
2. Roth, P. Stanley, E. R. (1992) The biology of CSF-1 and its receptor. Curr. Top. Microbiol. Immunol. 181, 141-167.
3. Hansson, G. K., Holm, J., and Jonasson, L. (1989) Detection of activated T lymphocytes in the human atherosclerotic plaque. Am. J. Pathol. 135, 169-175.
4. Pasceri, V., Willerson, J. T., and Yeh, E. T. (2000) Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102, 2165-2168.
5. Myllarniemi, M., Calderon, L., Lemstrom, K., Buchdunger, E., and Hayry, P. (1997) Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation. FASEB J. 11, 1119-1126.
6. Uzui, H., Harpf, A., Liu, M., Doherty, T. M., Shukla, A., Chai, N. N., Tripathi, P. V., Jovinge, S., Wilkin, D. J., Asotra, K., Shah, P. K., Rajavashisth, T. B. (2002) Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines. Circulation 106, 3024-3030.
7. Schonbeck, U. and Libby, P. (2001) CD40 signaling and plaque instability. Circ. Res. 89, 1092-1103.
8. Lacraz, S., Nicod, L., Galve-de Rochemonteix, B., Baumberger, C., Dayer, J. M., and Welgus, H. G. (1992) Suppression of metalloproteinase biosynthesis in human alveolar macrophages by interleukin-4. J. Clin. Invest. 90, 382-388.
9. Geng, Y. J., Wu, Q., Muszynski, M., Hansson, G. K., and Libby, P. (1996) Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-γ, tumor necrosis factor-α, and interleukin-1β. Arterioscler. Thromb. Vasc. Biol. 16, 19-27.
10. Blaschke, F., Bruemmer, D., Yin, F., Takata, Y., Wang, W., Fishbein, M. C., Okura, T., Higaki, J., Graf, K., Fleck, E., Hsueh, W. A., Law, R. E. (2004) C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells. Circulation 110, 579-587.
11. Amento, E., Ehsani, N., and Libby, P. (1991) Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler. Thromb. 11, 1223-1230.
12. Robertson, A. K. L., Rudling, M., Zhou, X., Gorelik, L., Flavell, R. A., and Hansson, G. K. (2003) Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J. Clin. Invest. 112, 1342-1350.
13. D'Andrea, A., Aste-Amezaga, M., Valiante, N. M., Ma, X., Kubin, M., and Trinchieri, G. (1993) Interleukin 10 (IL-10) inhibits human lymphocyte interferon-g production by suppressing natural killer cell stimulatory factor: IL-12 synthesis in accessory cells. J. Exp. Med. 178, 1041-1048.
14. Grainger, D. J., Kemp, P. R., Witchell, C. M., Weissberg, P. L., and Metcalfe, J. C. (1994) Transforming growth factor beta decreases the rate of proliferation of rat vascular smooth muscle cells by extending the G2 phase of the cell cycle and delays the rise in cyclic AMP before entry into M phase. Biochem. J. 299, 227-235.
15. Haider, M., Rizvi, M., Malik, A., Azam, M., and Rabbani, M. U. (2011) Acute and chronic Chlamydia pneumoniae infection and inflammatory markers in coronary artery disease patients. J. Infect. Dev. Ctries. 12, 580-586.
16. Pieringer, H. and Pichler, M. (2011) Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications. QJM 104, 13-26.
17. Mirjafari, H., Al-Husain, A., and Bruce, I. N. (2011) Cardiovascular risk factors in inflammatory arthritis. Curr. Opin. Lipidol. 22, 296-301.
18. Espinola-Klein, C., Gori, T., Blankenberg, S., and Munzel, T. (2011) Inflammatory markers and cardiovascular risk in the metabolic syndrome. Front. Biosci. 1, 1663-1674.
19. Grau, A. J., Boddy, A. W., Dukovic, D. A., Buggle, F., Lichy, C., Brandt, T., Hacke, W.; CAPRIE Investigators. (2004) Leukocyte count as an independent predictor of recurrent ischemic events. Stroke 35, 1147-1152.
20. Margolis, K. L., Manson, J. E., Greenland, P., Rodabough, R. J., Bray, P.F. Grimm, R. H. Jr., Howard, B. V., Assaf, A. R., Prentice, R.; Women's Health Initiative Research Group. (2005) Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study. Arch. Intern. Med. 165, 500-508.
21. Sabatine, M. S., Morrow, D. A., Cannon, C. P., Murphy, S. A., Demopoulos, L. A., DiBattiste, P. M., McCabe, C. H., Braunwald, E., Gibson, C. M. (2002) Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 substudy. J. Am. Coll. Cardiol. 40, 1761-1768.
22. Horne, B. D., Anderson, J. L., John, J. M., Weaver, A., Bair, T. L., Jensen, K. R., Renlund, D. G., Muhlestein, J. B. Weaver, A., Bair, T. L., Jensen, K. R., Renlund, D. G., Muhlestein, J. B. Weaver, A., Bair, T. L., Jensen, K. R., Renlund, D. G., Muhlestein, J. B. Weaver, A., Bair, T. L., Jensen, K. R., Renlund, D. G., Muhlestein, J. B.; Intermountain Heart Collaborative Study Group. (2005) Which white blood cell subtypes predict increased cardiovascular risk? J. Am. Coll. Cardiol. 45, 1638-1643.
23. Ikonomidis, I., Andreotti, F., Economou, E., Stefanadis, C., Toutouzas, P., and Nihoyannopoulos, P. (1999) Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 100, 793-798.
24. Ikonomidis, I., Andreotti, F., and Nihoyannopoulos, P. (2004) Reduction of daily-life ischaemia by aspirin in patients with angina: underlying link between thromboxane A2 and macrophage colony stimulating factor. Heart 90, 289-293.
25. Rallidis, L. S., Zolidaki, M. G., Manioudaki, H. S., Laoutaris, N. P., Velissaridou, A. H., and Papasteriadis, E. G. (2002) Prognostic value of C-reactive protein, fibrinogen, interleukin 6 and macrophage colony stimulating factor in severe unstable angina. Clin. Cardiol. 25, 461-466.
26. Ikonomidis, I., Lekakis, J., Revela, I., Andreotti, F., and Nihoyannopoulos, P. (2005) Increased circulating C-reactive protein and macrophage colony stimulating factor are complementary predictors of long-term outcome in patients with chronic coronary artery disease. Eur. Heart J. 26, 1618-1624.
27. Ridker, P. M., Rifai, N., Stampfer, M. J., and Hennekens, C. H. Plasma concentration of IL-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101, 1767-1772.
28. Finkel, M. S., Hoffman, R. A., Shen, L., Oddis, C. V., Simmons, R. L., and Hattler, B. G. (1993) Interleukin 6 as a mediator of stunned myocardium. Am. J. Cardiol. 71, 1231-1232.
29. Deng, M. C., Erren, M., Lütgen, A., Zimmermann, P., Brisse, B., Schmitz, W., Assmann, G., Breithardt, G., Scheld, H. H. (1996) Interleukin 6 correlates with hemodynamic impairment during dobutamine administration in chronic heart failure. Int. J. Cardiol. 57, 129-134.
30. Ikonomidis, I., Athanassopoulos, G., Lekakis, J., Venetsanou, K., Marinou, M., Stamatelopoulos, K., Cokkinos, D. V., Nihoyannopoulos, P. (2005) Myocardial ischemia induces interleukin 6 and tissue factor production in patients with coronary artery disease. A dobutamine stress echocardiography study. Circulation 112, 3272-3279.
31. Ikonomidis, I., Athanassopoulos, G., Stamatelopoulos, K., Lekakis, J., Revela, I., Venetsanou, K., Marinou, M., Monaco, C., Cokkinos, D. V., Nihoyannopoulos, P. (2008) Additive prognostic value of interleukin 6 at peak phase of dobutamine stress echocardiography in patients with coronary artery disease. A 6-year follow-up study. Am. Heart J. 156, 269-276.
32. de Lemos, J. A., Morrow, D. A., Sabatine, M. S., Murphy, S. A., Gibson, C. M., Antman, E. M., McCabe, C. H., Cannon, C. P., Braunwald, E. (2003) Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 107, 690-695.
33. Kervinen, H., Mänttäri, M., Kaartinen, M., Mäkynen, H., Palosuo, T., Pulkki, K., Kovanen, PT. (2004) Prognostic usefulness of plasma monocyte/macrophage and T-lymphocyte activation markers in patients with acute coronary syndromes. Am. J. Cardiol. 94, 993-996.
34. de Lemos, J. A., Morrow, D. A., Blazing, M. A., Jarolim, P., Wiviott, S. D., Sabatine, M. S., Califf, R. M., Braunwald, E. (2007) Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes. Results from the A to Z trial. J. Am. Coll. Cardiol. 50, 2117-2124.
35. Tuomisto, K., Jousilahti, P., Sundvall, J., Pajunen, P., and Salomaa, V. (2006) C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. Thromb. Haemostat. 95, 511-518.
36. Kiechl, S., Schett, G., Wenning, G., Redlich, K., Oberhollenzer, M., Mayr, A., Santer, P., Smolen, J., Poewe, W., Willeit, J. (2004) Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109, 2175-2180.
37. Jono, S., Ikari, Y., Shioi, A., Mori, K., Miki, T., Hara, K., Nishizawa, Y. (2002) Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 106, 1192-1194.
38. Palazzuoli, A., Rizzello, V., Calabró, A., Gallotta, M., Martini, G., Quatrini, I., Campagna, M. S., Franci, B., Nuti, R. (2008) Osteoprotegerin and B-type natriuretic peptide in non-ST elevation acute coronary syndromes: relation to coronary artery narrowing and plaques number. Clin. Chim. Acta 391, 74-79.
39. Zwaka, T. P., Hombach, V., and Torzawski, J. (2001) C-reactive protein-mediated low density lipoprotein uptake by macrophages implications for atherosclerosis. Circulation 111, 1194-1197.
40. Ridker, P. M., Buring, J. E., Cook, N. R., and Rifai, N. (2003) C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation 107, 391-397.
41. Danesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D., Pepys, M. B., Gudnason, V. (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 250, 1287-1297.
42. Ridker, P. M. and Cook, N. (2004) Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. Circulation 109, 1955-1959.
43. Heeschen, C., Hamm, C. W., Bruemmer, J., and Simmons, M. L. (2000) Predictive value of C-reactive protein and Troponin T in patients with unstable angina: a comparative analysis. CAPTURE investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J. Am. Coll. Cardiol. 35, 1535-1542.
44. Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Crowe, T., Sasiela, W. J., Tsai, J., Orazem, J., Magorien, R. D., O'Shaughnessy, C., Ganz, P.; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. (2005) Statin therapy, LDL cholesterol, C-reactive protein and coronary artery disease. N. Engl. J. Med. 352, 29-38.
45. deFilippi, C., Wasserman, S., Rosanio, S., Tiblier, E., Sperger, H., Tocchi, M., Christenson, R., Uretsky, B., Smiley, M., Gold, J., Muniz, H., Badalamenti, J., Herzog, C., Henrich, W. (2003) Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 290, 353-359.
46. Apple, F. S., Murakami, M. M., Pearce, L. A., and Herzog, C. A. (2004) Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high sensitivity C-reactive protein, and cardiac Troponin T and I in end-stage renal disease for all-cause death. Clin. Chem. 50, 2279-2285.
47. Zethelius, B., Berglund, L., Sundström, J., Ingelsson, E., Basu, S., Larsson, A., Venge, P., Arnlöv, J. (2008) Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N. Engl. J. Med. 358, 2107-2116.
48. Sabatine, M. S., Morrow, D. A., de Lemos, J. A., Gibson, C. M., Murphy, S. A., Rifai, N., McCabe, C., Antman, E. M., Cannon, C. P., Braunwald, E. (2002) Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin-I, C-reactive protein and B-type natriuretic peptide. Circulation 105, 17760-17763.
49. Wiviott, S. D., Cannon, C. P., Morrow, D. A., Murphy, S. A., Gibson, C. M., McCabe, C. H., Sabatine, M. S., Rifai, N., Giugliano, R. P., DiBattiste, P. M., Demopoulos, L. A., Antman, E. M., Braunwald, E. (2004) Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI-18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. Circulation 109, 580-586.
50. Asano, K., Okamoto, S., Fukunaga, K., Shiomi, T., Mori, T., Iwata, M., Ikeda, Y., Yamaguchi, K. (1999) Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem. Biophys. Res. Commun. 261, 511-514.
51. Tselepis, A. D. and Chapman, M. J. (2002) Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase. Atheroscler. Suppl. 3, 57-68.
52. Häkkinen, T., Luoma, J. S., Hiltunen, M. O., Macphee, C. H., Milliner, K. J., Patel, L., Rice, S. Q., Tew, D. G., Karkola, K., Ylä-Herttuala, S. (1999) Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 19, 2909-2917.
53. Packard, C. J., O'Reilly, D. S., Caslake, M. J., McMahon, A. D., Ford, I., Cooney, J., Macphee, C. H., Suckling, K. E., Krishna, M., Wilkinson, F. E., Rumley, A., Lowe, G. D. (2000) Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N. Engl. J. Med. 343, 1148-1155.
54. Brilakis, E. S., McConnell, J. P., Lennon, R. J., Elesber, A. A., Meyer, J. G., Berger, P. B. (2005) Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur. Heart J. 26, 137-144.
55. Ikonomidis, I., Michalakeas, C. A., Lekakis, J., Parissis, J., and Anastasiou-Nana, M. (2011) The role of lipoprotein-associated phospholipase A2 (Lp-PLA2) in cardiovascular disease. Rev. Recent Clin. Trials 6, 108-113.
56. Ballantyne, C., Hoogeveen, R., Bang, H., Coresh, J, Folsom, A. R., Heiss, G., Sharrett, A. R. (2004) Lipoprotein-associated phospholipase A2, high sensitive C-reactive protein and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109, 837-842.
57. Oei, H. H., van der Meer, I. M., Hofman, A., Koudstaal, P. J., Stijnen, T., Breteler, M. M., Witteman, J. C. (2005) Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 111, 570-575.
58. Koenig, W., Twardella, D., Brenner, H., and Rothenbacher, D. (2006) Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler. Thromb. Vasc. Biol. 26, 1586-1593.
59. Frostegård, J., Ulfgren, A. K., Nyberg, P., Hedin, U., Swedenborg, J., Andersson, U., Hansson, G. K. (1999) Cytokine expression in advanced plaques: dominance of proinflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145, 33-43.
60. Kojima, S., Harpel, P. C., and Rifkin, D. B. (1991) Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J. Cell. Biol. 113, 1439-1445.
61. Kollias, A., Tsiotra, P. C., Ikonomidis, I., Maratou, E., Mitrou, P., Kyriazi, E., Boutati, E., Lekakis, J., Economopoulos, T., Kremastinos, D. T., Dimitriadis, G., and Raptis, S. A. (2011) Adiponectin levels and expression of adiponectin receptors in isolated monocytes from overweight patients with coronary artery disease. Cardiovasc. Diabetol. 10, 14.
62. Kyriazi, E., Tsiotra, P. C., Boutati, E., Ikonomidis, I., Fountoulaki, K., Maratou, E., Lekakis, J., Dimitriadis, G., Kremastinos, D. T., and Raptis, S. A. (2011) Effects of adiponectin in TNF-α, IL-6, and IL-10 cytokine production from coronary artery disease macrophages. Horm. Metab. Res. 43, 537-544.
63. Ikonomidis, I., Michalakeas, C. A., Lekakis, J., Paraskevaidis, I., and Kremastinos, D. T. Multimarker approach in cardiovascular risk prediction. Dis. Markers 26, 273-285.
64. Cesari, M., Penninx, B. W., Newman, A. B., Kritchevsky, S. B., Nicklas, B. J., Sutton-Tyrrell, K., Rubin, S. M., Ding, J., Simonsick, E. M., Harris, T. B., Pahor, M. (2003) Inflammatory markers and onset of cardiovascular events: Results from the Health ABC study. Circulation 108, 2317-2322.
65. Vasan, R. S., Sullivan, L. M., Roubenoff, R., Dinarello, C. A., Harris, T., Benjamin, E. J., Sawyer, D. B., Levy, D., Wilson, P. W., and D'Agostino, R. B. (2003) Framingham Heart Study. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial nfarction: the Framingham Heart Study. Circulation 25, 1486-1491.
66. Folsom, A. R., Chambless, L. E., Ballantyne, C. M., Coresh, J., Heiss, G., Wu, K. K., Boerwinkle, E., Mosley, T. H. Jr., Sorlie, P., Diao, G., Sharrett, A. R. (2006) An assessment of incremental risk prediction using C-reactive protein and other novel risk biomarkers: the atherosclerosis risk in communities study. Arch. Intern. Med. 166, 1368-1373.
67. Ikonomidis, I., Lekakis, J., Stamatelopoulos, K., Vamvakou, G., and Kremastinos, D. (2008) Inflammatory and non-invasive markers: The multimarker approach for risk stratification in coronary artery disease. Atherosclerosis 199, 3-11.
68. KoukkuneN, H., Penttilä, K., Kemppainen, A., Halinen, M., Penttila, I., Rantanen, T., Pyörälä, K. (2001) C-reactive protein, fibrinogen, interleukin-6 and tumor necrosis factor-alpha in the prognostic classification of unstable angina pectoris. Ann. Med. 33, 37-47.
69. Anand, I. S., Latini, R., Florea, V. G., Kuskowski, M. A., Rector, T., Masson, S., Signorini, S., Mocarelli, P., Hester, A., Glazer, R., Cohn, J. N.; Val-HeFT Investigators. (2005) C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 112, 1428-1434.
70. Sabatine, M. S., Morrow, D. A., O'Donoghue, M., Jablonski, K. A., Rice, M. M., Solomon, S., Rosenberg, Y., Domanski, M. J., Hsia, J.; PEACE Investigators. (2007) Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 27, 2463-2469.
71. Möckel, M., Danne, O., Müller, R., Vollert, J. O., Müller, C., Lueders, C., Störk, T., Frei, U., Koenig, W., Dietz, R., Jaffe, A. S. (2008) Development of an optimized biomarker strategy for early risk assessment of patients with acute coronary syndromes. Clin. Chim. Acta 393, 103-109.
72. Oudi, M. E., Aouni, Z., Mazigh, C., Khochkar, R., Gazoueni, E., Haouela, H., and Machghoul, S. (2010) Homocysteine and markers of inflammation in acute coronary syndrome. Exp. Clin. Cardiol. 15, 25-28.
73. Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M. Jr., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., Nordestgaard, B. G., Shepherd, J., Willerson, J. T., Glynn, R. J.; JUPITER Study Group. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195-2207.
74. Basterzi, A. D., Aydemir, C., Kisa, C., Aksaray, S., Tuzer, V., Yazici, K., and Goka, E. (2005) IL-6 levels decrease with SSRI treatment in patients with major depression. Hum. Psychopharmacol. 20, 473-476.
75. Lekakis, J., Ikonomidis, I., Papoutsi, Z., Moutsatsou, P., Nikolaou, M., Parissis, J., and Kremastinos, D. T. (2010) Selective serotonin re-uptake inhibitors decrease the cytokine-induced endothelial adhesion molecule expression, the endothelial adhesiveness to monocytes and the circulating levels of vascular adhesion molecules. Int. J. Cardiol. 139, 150-158.
76. Michalakeas, C. A., Parissis, J. T., Douzenis, A., Nikolaou, M., Varounis, C., Andreadou, I., Antonellos, N., Markantonis-Kiroudis, S., Paraskevaidis, I., Ikonomidis, I., Lykouras, E., and Kremastinos, D. (2011) Effects of sertraline on circulating markers of oxidative stress in depressed patients with chronic heart failure: a pilot study. J. Card. Fail. 17, 748-754.
77. Ikonomidis, I., Tzortzis, S., Lekakis, J., Paraskevaidis, I., Dasou, P., Parissis, J., Nikolaou, M., Markantonis, S. L., Katsimbri, P., Skarantavos, G., Andreadou, I., and Anastasiou-Nana, M. (2011) Association of soluble apoptotic markers with impaired left ventricular deformation in patients with rheumatoid arthritis. Effects of inhibition of interleukin-1 activity by anakinra. Thromb. Haemost. 106, 959-967.
78. Ikonomidis, I., Papadimitriou, C., Vamvakou, G., Katsichti, P., Venetsanou, K., Stamatelopoulos, K., Papamichael, C., Dimopoulos, A. M., and Lekakis, J. (2008) Treatment with granulocyte colony stimulating factor is associated with improvement in endothelial function. Growth Factors 26, 117-124.
79. Serruys, P. W., García-García, H. M., Buszman, P., Erne, P., Verheye, S., Aschermann, M., Duckers, H., Bleie, O., Dudek, D., Bøtker, H. E., von Birgelen, C., D'Amico, D., Hutchinson, T., Zambanini, A., Mastik, F., van Es, G. A., van der Steen, A. F., Vince, D. G., Ganz, P., Hamm, C. W., Wijns, W., Zalewski, A.; Integrated Biomarker and Imaging Study-2 Investigators. (2008) for the Integrated Biomarker and Imaging Study-2 Investigators. Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118, 1172-1182.
80. Fayad, Z. A., Mani, V., Woodward, M., Kallend, D., Bansilal, S., Pozza, J., Burgess, T., Fuster, V., Rudd, J. H., Tawakol, A., and Farkouh, M. E. (2011) Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Am. Heart J. 162, 214-221.
81. Khanzode, S. D., Dakhale, G. N., Khanzode, S. S., Saoji, A., Palasodkar, R. (2003) Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep. 8, 365-370.
82. Abbate, A., Salloum, F. N., Vecile, E., Das, A., Hoke, N. N., Straino, S., Biondi-Zoccai, G. G., Houser, J. E., Qureshi, I. Z., Ownby, E. D., Gustini, E., Biasucci, L. M., Severino, A., Capogrossi, M. C., Vetrovec, G. W., Crea, F., Baldi, A., Kukreja, R. C., and Dobrina, A. (2008) Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 117, 2670-2683.
83. Ikonomidis, I., Lekakis, J. P., Nikolaou, M., Paraskevaidis, I., Andreadou, I., Kaplanoglou, T., Katsimbri, P., Skarantavos, G., Soucacos, P. N., Kremastinos, D. T. (2008) Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation 117, 2662-2669.
84. Ikonomidis, I., Tzortzis, S., Lekakis, J., Paraskevaidis, I., Andreadou, I., Nikolaou, M., Kaplanoglou, T., Katsimbri, P., Skarantavos, G., Soucacos, P., and Kremastinos, D. T. (2009) Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. Heart 95, 1502-1507.
85. White, H., Held, C., Stewart, R., Watson, D., Harrington, R., Budaj, A., Steg, P. G., Cannon, C. P., Krug-Gourley, S., Wittes, J., Trivedi, T., Tarka, E., and Wallentin, L. (2010) Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am. Heart J. 160, 655-661.
86. O'Donoghue, M. L., Braunwald, E., White, H. D., Serruys, P., Steg, P. G., Hochman, J., Maggioni, A. P., Bode, C., Weaver, D., Johnson, J. L., Cicconetti, G., Lukas, M. A., Tarka, E., and Cannon, C. P. (2011) Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am. Heart J. 162, 613-619.